Abeona Therapeutics (ABEO) Fundamentals 2026 — P/E 5.0x, Revenue Analysis | SniperIQ
Abeona Therapeutics (ABEO) is a US-listed Healthcare company in Biotechnology with a market capitalization of
Abeona Therapeutics (ABEO) has a market capitalization of approximately
Abeona Therapeutics's trailing twelve-month P/E ratio is 5.0x, with a price-to-book (P/B) of 2.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
Abeona Therapeutics runs a net profit margin of 454.9%, a gross margin of 51.9%, and an operating margin of -637.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Abeona Therapeutics reported revenue of $6M for fiscal year 2025, with net income of $71M and earnings per share (EPS) of 1.34. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Abeona Therapeutics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Abeona Therapeutics carries a debt-to-equity ratio of 0.16x and a current ratio of 5.89x, with a market beta of 1.33. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Abeona Therapeutics (ABEO) the key facts are: market cap
Get Abeona Therapeutics's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.